IP Library Granted Patent US 7,643,521
Granted Patent B2
US 7,643,521 · App. 11/460,567 · Granted Jan 5, 2010

Material processing system with variable repetition rate laser

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,643,521
App. No.
11/460,567
Granted
Jan 5, 2010
Kind
B2
Abstract

A system for using a pulsed laser beam to process materials includes a selector for varying the pulse repetition rate of the laser beam. Also included is a control unit for identifying an optimal pulse repetition rate that is compatible with the required pulse energy level for processing the material. Variations in the pulse repetition rate can be made during a procedure pursuant to either pre-programmed instructions, or in response to closed loop feedback controls.

Claims (34)

1. A system for processing materials which comprises:

a laser source for generating a beam of laser pulses having a required first pulse repetition rate (R 1 ) with a first predetermined energy level in each laser pulse to process a first material at a first target area, and for alternately generating a required second pulse repetition rate (R 2 ) with a second predetermined energy level in each laser pulse to process a second material at a second target area, wherein the first material is contiguous with and different from the second material;

an optical means for directing the laser beam to the respective target areas in the material to alter the respective material therein with an interaction to induce a characteristically identifiable response from the respective material;

a detector for monitoring the identifiable response in the respective material; and

a switch for changing between the first required pulse repetition rate R 1 and the second required pulse repetition rate R 2 in response to changes in the identifiable response in the material.

2. A system as recited in claim 1 wherein an interaction is a laser induced optical breakdown (LIOB), wherein the material is a substantially transparent material, and wherein the first required pulse repetition rate (R 1 ) is maintained by the selector for use on a procedure section having a relatively high energy processing requirement (P 1 ), and the second required pulse repetition rate (R 2 ) is maintained by the selector for use on a procedure section having a relatively low energy processing requirement (P 2 ), and wherein R 1 is less than R 2 (R 1 <R 2 ).

3. A system as recited in claim 1 wherein the identifiable response is a gas bubble and the switch changes between R 1 and R 2 in response to a predetermined change in the diameter of the gas bubble.

4. A system as recited in claim 1 wherein an interaction is selected from a group consisting of laser induced optical breakdown (LIOB), photodecomposition, and photoablation.

5. A system as recited in claim 4 wherein the identifiable response from photoablation is a plasma spark.

6. A system as recited in claim 1 wherein establishment of the required pulse repetition rate is accomplished by a selector in accordance with a pre-programmed procedure.

7. A system as recited in claim 1 wherein establishment of the required pulse repetition rate is accomplished by a selector in response to closed loop feedback control.

8. A system as recited in claim 1 wherein an optical means directs the laser beam along a path through the material.

9. A system as recited in claim 1 wherein each laser pulse has a duration in a range including femtoseconds and picoseconds.

10. A system for processing materials with a required energy level which comprises:

a laser source for generating a beam of laser pulses having a pulse repetition rate variable between a required first pulse repetition rate (R 1 ) with a first predetermined energy level in each laser pulse to process a first material at a first target area, and for alternately generating a required second pulse repetition rate (R 2 ) with a second predetermined energy level in each laser pulse to process a second material at a second target area, wherein the first material is contiguous with and different from the second material;

an optical means for directing the laser beam to a target area in the respective material to alter the material therein with an interaction to induce a characteristically identifiable response from the respective material;

a means for identifying a required pulse repetition rate to achieve the required energy level at the target area;

a means for establishing the required pulse repetition rate to maintain the required energy level in the laser pulses for processing the material;

a monitoring means for detecting the identifiable response in the respective material; and

a means for changing between the first required pulse repetition rate R 1 and the second required pulse repetition rate R 2 in response to changes in the identifiable response in the material.

11. A system as recited in claim 10 wherein an identifying means is a control unit and an establishing means is a selector.

12. A system as recited in claim 10 wherein the material is a substantially transparent material, and wherein the first required pulse repetition rate (R 1 ) is maintained by a selector for use on a procedure section having a relatively high energy processing requirement (P 1 ), and the second required pulse repetition rate (R 2 ) is maintained by the selector for use on a procedure section having a relatively low energy processing requirement (P 2 ), and wherein R 1 is less than R 2 (R 1 <R 2 ).

13. A system as recited in claim 10 wherein the identifiable response is a gas bubble and a switch changes between R 1 and R 2 in response to a predetermined change in the diameter of the gas bubble.

14. A method for processing materials which comprises the steps of:

determining a required energy level for processing the material;

providing a laser source for generating a beam of laser pulses having a pulse repetition rate variable between a required first pulse repetition rate (R 1 ) with a first predetermined energy level in each laser pulse to process a first material at a first target area, and for alternately generating a required second pulse repetition rate (R 2 ) with a second predetermined energy level in each laser pulse to process a second material at a second target area, wherein the first material is contiguous with and different from the second material;

directing the laser beam to a target area in the respective material;

identifying a required pulse repetition rate to achieve the required energy level at the target area;

establishing the required pulse repetition rate to maintain the required energy level in the laser pulses for processing the material;

monitoring the identifiable response in the respective material resulting from the establishing step; and

changing between the first required pulse repetition rate R 1 and the second required pulse repetition rate R 2 in response to changes in the identifiable response in the material.

15. A method recited in claim 14 further comprising the steps of:

maintaining the first required pulse repetition rats (R 1 ) for use on a procedure section having a relatively high energy processing requirement (P 1 ); and

maintaining the second required pulse repetition rate (R 2 ) for use on a procedure section having a relatively low energy processing requirement (P 2 ), and wherein R 1 is less than R 2 (R 1 <R 2 ).

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →